JP2013507414A - 神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト - Google Patents

神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト Download PDF

Info

Publication number
JP2013507414A
JP2013507414A JP2012533580A JP2012533580A JP2013507414A JP 2013507414 A JP2013507414 A JP 2013507414A JP 2012533580 A JP2012533580 A JP 2012533580A JP 2012533580 A JP2012533580 A JP 2012533580A JP 2013507414 A JP2013507414 A JP 2013507414A
Authority
JP
Japan
Prior art keywords
mmol
dmf
arg
tyr
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012533580A
Other languages
English (en)
Japanese (ja)
Inventor
コンデ−ネイプ，カリン
ダンホ，ウォリード
フトゥヒ，ナデル
フライ，デイビッド・シー
カーン，ワジハ
コンカー，アニッシュ
ロンディノーネ，クリスティーナ・マーサ
スウィストク，ジョセフ
ティリー，ジェファーソン・ライト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2013507414A publication Critical patent/JP2013507414A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2012533580A 2009-10-13 2010-10-08 神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト Ceased JP2013507414A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25089609P 2009-10-13 2009-10-13
US61/250,896 2009-10-13
PCT/EP2010/065060 WO2011045232A2 (en) 2009-10-13 2010-10-08 Neuropeptide-2 receptor (y-2r) agonists

Publications (1)

Publication Number Publication Date
JP2013507414A true JP2013507414A (ja) 2013-03-04

Family

ID=43478048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012533580A Ceased JP2013507414A (ja) 2009-10-13 2010-10-08 神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト

Country Status (7)

Country Link
US (1) US20110172147A1 (enExample)
EP (1) EP2488195A2 (enExample)
JP (1) JP2013507414A (enExample)
CN (1) CN102596228A (enExample)
CA (1) CA2776302A1 (enExample)
IN (1) IN2012DN03042A (enExample)
WO (1) WO2011045232A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
EP2708243A1 (en) * 2012-09-17 2014-03-19 OntoChem GmbH Receptor ligand linked cytotoxic molecules
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
WO2015071355A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX392572B (es) 2015-06-12 2025-03-24 Novo Nordisk As Compuestos del péptido yy (pyy) selectivos y sus usos.
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CN109678930B (zh) * 2018-12-05 2022-04-29 西北工业大学 聚乙二醇修饰的npff及其用途
CN120092752B (zh) * 2025-05-09 2026-04-07 北京大学人民医院 三叉神经痛动物模型及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB779829A (en) 1953-11-20 1957-07-24 Ciba Ltd Polyglycol ethers and their manufacture
BE667886A (enExample) 1965-04-23
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5962263A (en) * 1998-01-08 1999-10-05 Incyte Pharmaceuticals, Inc. Human membrane recycling proteins
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
WO2006049681A2 (en) * 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006091505A2 (en) * 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists
EP1962959B1 (en) * 2005-12-07 2012-03-14 F. Hoffmann-La Roche AG Neuropeptide-2 receptor-agonists
EP2198301B1 (en) * 2007-09-11 2015-04-08 Kode Biotech Limited Peptide-lipid constructs and their use in diagnostic and therapeutic applications
BRPI0921230A2 (pt) * 2008-11-05 2018-10-30 Hoffmann La Roche agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.

Also Published As

Publication number Publication date
US20110172147A1 (en) 2011-07-14
WO2011045232A2 (en) 2011-04-21
CN102596228A (zh) 2012-07-18
IN2012DN03042A (enExample) 2015-07-31
WO2011045232A3 (en) 2011-06-16
CA2776302A1 (en) 2011-04-21
EP2488195A2 (en) 2012-08-22

Similar Documents

Publication Publication Date Title
RU2383553C2 (ru) Пептиды, обладающие агонистической активностью в отношении рецептора нейропептида-2-(y2r)
US20110172147A1 (en) Neuropeptide-2 receptor (y-2r) agonists
US20100179093A1 (en) Neoropeptide-2-Receptor (Y-2R) Agonists
DK2320923T3 (en) Truncated analogues of glucose-dependent insulinotropic polypeptide
JP5000663B2 (ja) 神経ペプチド２受容体アゴニスト
US20100331245A1 (en) Peptide yy analogs
US20100069307A1 (en) Neuropeptide-2 receptor (y-2r) agonists
KR20130127985A (ko) 글루코스-의존 인슐린 친화성 펩티드 유사체
MX2008007186A (en) Neuropeptide-2 receptor-agonists
HK1126154A (en) Neuropeptide-2 receptor-agonists

Legal Events

Date Code Title Description
A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A043

Effective date: 20130806